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Abstract
Background and Purpose: Adjuvant radiotherapy for cancer can result in severe adverse side effects for normal
tissues. In this respect, individuals with anomalies of the ATM (ataxia telangiectasia) protein/gene are of particular
interest as they may be at risk of both breast cancer and clinical radiosensitivity. The association of specific ATM
gene mutations with these pathologies has been well documented, however, there is uncertainty regarding
pathological thresholds for the ATM protein.
Results: Semi-quantitative immuno-blotting provided a reliable and reproducible method to compare levels of the
ATM protein for a rare cohort of 20 cancer patients selected on the basis of their severe adverse normal tissue
reactions to radiotherapy. We found that 4/12 (33%) of the breast cancer patients with severe adverse normal
tissue reactions following radiotherapy had ATM protein levels < 55% compared to the mean for non-reactor
controls.
Conclusions: ATM mutations are generally considered low risk alleles for breast cancer and clinical radiosensitivity.
From results reported here we propose a tentative ATM protein threshold of ~55% for high-risk of clinical
radiosensitivity for breast cancer patients.
Background
Primary treatment for organ-confined breast cancer usually
involves a combination of limited breast-conservation
surgery and radiotherapy yielding control rates equivalent
to mastectomy. Such radiotherapy is usually tolerated well
except for the very small percentage of patients who
experience severe adverse normal tissue reactions
(RTOG3-4 reactions) [1]. There is little empirical evidence
to support anecdotal reports of clinical radiosensitivity in
connective tissue disorders including systemic lupus
erythematosus (SLE) [2-5]. However, other genetic predis-
positions, including autosomal recessive ataxia telangiecta-
sia (A-T), have a clear association with clinical
radiosensitivity [6,7]. A-T is an autosomal recessive disor-
der characterised by early-onset neurodegeneration,
oculocutaneous telangiectasia, immunodeficiency, hypogo-
nadism, cancer susceptibility and acute hypersensitivity to
radiotherapy [6]. ATM, the susceptibility gene for A-T,
encodes a protein kinase activated in response to ionising
radiation (IR) induced DNA double-strand breaks that
facilitates the phosphorylation of numerous molecular
intermediates involved in cell-cycle regulation and DNA
repair. A-T patients usually harbour compound ATM
mutations comprising either two non-allelic null mutations
or one null and one pathogenic missense mutation [7,8].
The approximately 1% of individuals in the general
population which are A-T heterozygotes [9,10] do not
present with any of the more severe early-onset A-T
pathologies, however, they are considered at risk of
breast cancer [9,11,12] and/or clinical radiosensitivity
[9]. Albeit, the level of risk associated with ATM muta-
tions is uncertain. In 2002 Inannuzzi et al [9] found that
a small cohort of clinically radiosensitive breast cancer
patients had a higher incidence of ATM missense var-
iants; unfortunately, no functional deficit was established
for any of these variants in the form of reduced levels of
either ATM protein or ATM kinase activity. In the
same year, we described the first heterozygous ATM
missense mutation causing dominant negative effects in
breast cancer including cellular radiosensitivity and
reduced ATM kinase activity but no obvious reduction
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in the level of the ATM protein [10]. However, not all
missesnse variants are associated with dominant nega-
tive effects. By comparison, individuals heterozygous for
one of the many reported ATM null mutations have
reduced levels of the ATM protein, albeit, these reduced
levels do not always appear to fall below the threshold
for risk of breast cancer and/or clinical radiosensitivity
[8,10,12-18]. For want of improving risk assessments for
breast cancer and radiosensitivity it would therefore be
advantageous to establish pathological threshold levels
for the ATM protein.
In the present study we used comparative immuno-
blotting of the ATM protein to investigate a cohort of
cancer patients selected on the basis of their severe
adverse reactions to adjuvant radiotherapy and com-
pared these with control patients with no adverse reac-
tions. We also compared ATM levels for a group of
women with SLE [19]. The radiosensitive breast cancer
patients in our cohort expressed a much wider range of
ATM protein levels compared with the non-reactor con-
trol group. Patients with low ATM levels were evaluated
further for ATM kinase activity, IR-induced chromoso-
mal aberrations (ICA) and ATM mutation status using
RT-PCR and genomic sequencing. For those individuals
with multiple ATM mutations we established allelic sta-
tus. Results suggest that ATM protein levels are useful
for identifying breast cancer patients at high-risk of clin-
ical radiosensitivity.
Methods
We obtained human ethics approval from the Institu-
tional Review Boards of the three institutions involved
in this study. We obtained informed consent from
paticipants in accordance with the guidelines set down
by the National Health and Medical Research Council
of Australia. In should be appreciated here that very
severe reactions to radiotherapy are particularly rare
entities and that it was only through close personal
communication between 3 of Australia’s major cancer
centres that we were able to assemble a cohort of 20
cancer patients that had had very severe adverse nor-
mal tissue reactions: The Cancer Care Centre, St
George Hospital, Sydney; Queensland Radium Institute,
Brisbane and Peter MacCallum Cancer Institute, Mel-
bourne, Australia. Courses of radiotherapy were uni-
formly delivered with 3-dimensional (3D) conformal
techniques using a linear accelerator (4 MV/6 MV) at
scheduled doses of 46 Gy in 20 fractions to the breast
with a boost of 10 Gy in five fractions to the primary
tumour excision site or 50 Gy in 25 fractions to the
chest wall post mastectomy. These patients were not
otherwise part of a clinical trial or any other organised
protocol. Acute toxicity was defined as toxicity from
the time of commencement of radiotherapy through to
the 90th day after treatment and late toxicity between
90 days and 5 years and assessment was based on the
RTOG grading system [20]. Severe acute or late toxi-
city was defined as ≥ grade 3.
2.1 Participants
Peripheral venous blood samples were collected from 52
consenting volunteers including 20 individuals with
severe adverse normal tissue reactions to radiotherapy,
for cancer of the cervix (2), prostate (6) and breast (12).
We also included breast cancer patients with no adverse
reactions (14); 11 women with SLE one of whom had
had previous treatment for breast cancer with no
adverse reaction to radiotherapy; 2 individuals with A-T
and 5 parents of A-T individuals (A-T obligate heterozy-
gotes), 4 of whom had ATM null-type mutations (see
results). We generated lymphoblastoid cell lines (LCLs)
from each paticipant. LCLs were maintained in RPMI
1640 medium supplemented with 10% foetal bovine
serum and 1% l-glutamine in a 5% CO2 atmosphere at
37°C.
Follow-up examinations were performed on a 3-4-
month basis for the 1st 2 years and 6 monthly for the
3rd and 4th years followed by a final appointment in the
5th year. A retrospective chart reviewing all radio-hyper-
sensitive patients was prepared, and morbidity data was
collected from the follow-up notes by a radiation oncol-
ogist who was unaware of the research results.
2.2 Comparative Western analysis of ATM protein levels
Antibodies
We used the ATM 2C1 monoclonal antibody (Abcam/
GeneTex) for ATM Western analysis and Kinase assays.
The constitutive level of the ATM protein for LCLs was
determined by western analysis using 4% polyacrylamide
gel electrophoresis as described previously [15]. Cell
extracts were initially denatured in SDS buffer (58 mM
TrisHCl, pH 6.8, 1.71% SDS (w/v), 0.83% (w/v) b-
mercaptoethanol, glycerol 6% (v/v), 0.002% (w/v)
bromophenol blue) at 100°C for 5 min and loaded onto
a 4% SDS PAGE gel. After electrophoresis proteins were
transferred to nylon membranes (1 hour) using a semi-
dry blotting apparatus (BioRad) and then stained with
Ponseau-S to confirm comparative protein loading and
transfer efficiency. Blots were washed in TBS-tween20
(TBS-T) and then blocked overnight at 4°C with 5%
skim milk in TBS-T.
Membranes were incubated with appropriate primary
antibodies diluted in 5% skim milk (ATM-2C1 primary
was used at 1:2,000 and the GAPDH primary antibody
was used at 1:15,000) in TBS for 1 hour, followed by 5
× washes with TBS-T at room temperature and then
incubated with the appropriate secondary antibody con-
jugates (HRP conjugated (Sigma) diluted 1:20,000) in
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10% skim milk in TBS for 30 min at room temperature,
followed by five washes with TBS-T at room tempera-
ture. Equivalent protein loading (50 μg) was confirmed
for each sample by comparing Ponseau S staining pat-
terns and by comparing immunoblot signals for a sec-
ond protein ~ glyceraldehyde phosphate dehydrogenase
(GAPDH) prior to probing with the ATM 2C1 antibody.
Western blots were imaged and analysed using a BioRad
imaging system. The individual with the highest level of
ATM protein was selected as the reference sample
termed the ‘highest expresser’. Band densities from
repeat experiments were averaged for each individual
and expressed as a percentage of the highest ATM
expresser similar to an earlier study by Richard Gatti’s
group [16]. The effect of IR on ATM protein levels was
similarly determined before and 1 hour after exposure
to IR (2 Gy) delivered by a linear accelerator [15,17].
We used the Student’s two-tailed t-test to determine the
significance of the findings.
2.3 In vitro ATM kinase assays
ATM protein kinase assays using GST-p53 as substrate
and ATM autophosphorylation assays were performed
essentially as described previously [18].
2.4 IR-induced chromosome aberrations
IR-induced chromosomal aberration (ICA) counts were
performed using an established technique described pre-
viously [21]. Cells were irradiated with 1 Gy of IR. For
G2-phase cells, colcemid at a final concentration of 100
ng/ml was added immediately after irradiation, 1 hour
before harvesting. The cells were treated for 15 min
with 0.075 M KCl, fixed in methanol-glacial acetic acid
(3:1) and spread on glass slides. The cells were then
stained with Giemsa and 50 metaphases were analysed
for each sample. The number of ICA that persisted 1
hour after exposure to IR was reported as average aber-
rations per metaphase.
2.5 Cell-growth delay assays after in vitro exposure to IR
Cell-doubling times were calculated prior to radiation
experiments. Using pre-conditioned medium, aliquots
of each LCL in log-phase were plated in precondi-
tioned media in 7 cm flasks at a density of approxi-
mately 5 × 104 cells/mL. Cells were incubated for 24
hours prior to irradiation with 2 Gy. Radiation was
delivered by a 6-MV linear accelerator with beam qual-
ity TPR2010 = 0.68 at a high dose rate of approxi-
mately 2.5 Gy/min. Cell-growth delay (SF2) values were
estimated relative to non-irradiated control cell lines
after four doubling times as the average of three repeat
experiments. Mean values for cohorts were expressed
as the cell-growth delay value ± the standard error
(SD/vn).
2.6 Nucleotide sequence analyses
Total RNA and genomic DNA were isolated from LCLs
using TRI-Reagent (Sigma Aldrich T9424). cDNA was
reverse transcribed using SuperScript III (Invitrogen
18080-044) and 500 ng of total RNA as template. The
full ATM transcript was PCR amplified as a series of 8
overlapping fragments as described previously [22-24].
PCR amplicons were electrophoresed on a 1% agarose
gel then excised and purified using the Perfectprep Gel
Cleanup Kit (Eppendorff) and subjected to forward and
reverse sequencing using the original PCR primer sets.
Sequence analysis was preformed using BioEdit Software
http://www.mbio.ncsu.edu/BioEdit/bioedit.html.
Intron/exon boundaries and variant nomenclature
were determined relative to RefSeq NM_000051 on the
LOVD ATM variant listings on web site http://chro-
mium.liacs.nl/lovd/refseq/ATM_codingDNA.html. DNA
mutation numbering was based on the cDNA sequence,
where +1 corresponds to A of the ATG translation
initiation codon. The initiation codon is counted as
codon 1.
Results
3.1 Patients and Radiotherapy
Patients with cancer of the breast, prostate and cervix
(reviewed in Table 1) were selected solely on the basis
of their severe adverse normal tissue reactions to radio-
therapy (RTOG3-4). Breast cancer patients 10, 12 and
13 had relatives also diagnosed with breast cancer
(Table 1). Severe late normal tissue reactions were
observed in 18/20 cancer patients and for 2 of these
(patients 10 & 11) the late reaction was preceded by a
severe acute reaction. Another 2 patients, patients 1 and
9, exhibited severe acute reactions only.
3.2 ATM Protein Levels
We determined ATM protein levels from LCLs estab-
lished from patients: 52 individuals in total. We referred
to the individual with the highest level of ATM protein
in cell extracts as the ‘highest expresser’. The highest
expresser was subsequently included as a reference lane
in repeat immunoblots (Fig. 1A lane 8, Fig. 1B lanes 1 &
8, Fig. 1C lanes 7 & 8). At least two different cell
extracts were analysed and averaged as a percentage of
the highest expresser using scatter plots (Fig. 2). The 14
breast cancer patients which had no adverse reaction to
radiotherapy, referred to here as ‘non-reactor controls’
(NRC see Fig. 2), had a mean level of the ATM protein
of 84% compared with the highest expresser (range 63%
- 100%). For the 2 A-T null cell lines we observed no
ATM expression [25]. For the 4 obligate A-T heterozy-
gotes (ATH) with null mutations the ATM protein
levels were > 55% (range 56% - 84%) compared to the
mean for non-reactor controls (Fig. 2). Unexpectedly,
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ATH5ABR, the A-T heterozygote control with a mis-
sense mutation (see below) was the lowest expresser of
all obligate heterozygotes with an ATM protein level
~14% compared to the highest expresser and ~17%
compared with the mean for non-reactor controls (Fig. 2
and see also Fig. 1A lane 10). Women with SLE (Fig. 2)
had ATM levels > 70% compared with the highest expres-
ser and a mean ATM protein level (87%) comparable to
the mean for non-reactor controls (84%) (Fig. 2).
Four of the twelve breast cancer patients with severe
late adverse normal tissue reactions to radiotherapy,
patients 10, 11, 13 and 16, had levels of ATM protein
~35%, ~45%, ~8% and ~30%, respectively, compared to
the highest expresser. These levels of the ATM protein
were all < 55% compared with the mean for non-reactor
controls (p = 0.0048) (Fig. 2 and see also Fig. 1A lanes 4
& 7, Fig. 1B lane 5 and Fig. 1C lanes 5 & 6). The
adverse late reactions to radiotherapy manifest by two
of these ‘low expressers’, patients 10 and 11, were
preceded by severe acute affects (Table 1). We over-
exposed western blots and found no noticeable expres-
sion of any novel ATM truncation products that might
otherwise ameliorate or compound the detrimental
effects of the low levels of ATM expression [26]. This
result was consistent with other studies reporting
instability of truncated proteins [27].
Patient 13 had the lowest ATM level of ~8% com-
pared to the highest expresser (Fig. 2 and see also
Fig. 1C lanes 5 & 6). This very low basal level of the
protein increased marginally following exposure to IR
(Fig. 1C and Fig. 3A &3B) comparable with the degree
of IR-induction of ATM protein level observed for the
highest expresser (Fig. 1C lanes 7 & 8). Note: the role of
this apparent stabilisation of the ATM protein following
exposure to IR is uncertain [15], whereas, the IR-induc-
tion of ATM kinase activity is a direct, but not quantita-
tive, measure of ATM function (see section 3.4).
3.3 Nucleotide Sequence Analysis
In the first instance we used RT-PCR to determine the
nucleotide sequence of the protein coding region of the
ATM transcript for the 4 low expresser patients. We
identified ATM point mutations for two of the low
expressers, patients 10 and 13. Patient 10 had a novel
missense mutation c.5557G>A:Asp1853Asn which was
confirmed by genomic sequencing of exon 39 (result
not shown). For patient 13 we identified a novel prema-
ture termination mutation c.1918A>T: Lys640Stop
(Fig. 3A) which was confirmed by genomic sequencing
of exon 15. In addition, the RT-PCR amplification of
fragment 1 for patient 13 was abnormal in that it gener-
ated a dual amplicon (lane 1 Fig. 3B). To investigate this
further, we compared the nucleotide sequence for both
the small and large amplicons and found that the smal-
ler amplicon was missing the nucleotide sequence for
exon 11 (Fig. 3C). Further genomic DNA sequencing in
Table 1 Clinical review for patients with adverse normal tissue reactions to radiotherapy
Patient Cancer Sex ATM% Age Reaction Clinical features
1 Prostate M 69 64 A RTOG4 - treatment terminated at 28 Gy
2 Prostate M 80 72 L RTOG3 - Proctitis
3 Prostate M 90 69 L RTOG3 - Proctitis
4 Prostate M 82 71 L RTOG3 - Proctitis
5 Prostate M 79 60 L RTOG3 - Cystitis
6 Prostate M 80 65 L RTOG3 - Proctitis
7 Cervix F 71 36 L RTOG3 - Urethral stricture
8 Cervix F 81 47 L RTOG3
9 Breast F 80 51 A RTOG3 - Moist desquamation
10*¥∞ Breast F 35 64 A&L RTOG4 - Familial Treatment terminated at 20 Gy
11*£¥ Breast F 45 54 A&L RTOG3 - Moist desquamation; skin atrophy/pigment
12 Breast F 82 57 L RTOG3 - Familial
13*∞£¥ Breast F 8 50 L RTOG4 - Familial, skin atrophy & fibrosis, necrosis
14 Breast F 77 41 L RTOG3 - Fibrosis (skin, subcutaneous tissue & breast)
15 Breast F 66 71 L RTOG4 - Familial
16*£ Breast F 30 77 L RTOG4
17 Breast F 64 47 L RTOG3
18 Breast F 88 58 L RTOG3
19 Breast F 69 62 L RTOG3
20 Breast F 66 70 L RTOG3
ATM% ~ percentage of ATM protein compared with the highest ATM expresser; * ~ low level of ATM protein < 50% cut-off;
A ~ severe acute reaction; L ~ severe late reaction; ¥ ~ Intermediate ICA count; ∞ ~ ATM mutation(s); £ ~ reduced ATM kinase activity.
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that region spanning the intron-exon boundaries adjoin-
ing exon 11 identified a heterozygous mutation c.1066-
6T>G (IVS10-6T>G) within the extended 5’ splice
consensus sequence of intron 10 (Fig. 3D). This muta-
tion generated an aberrant splice site recognition
sequence r.ex11del (1065del164) with potential to effect
skipping of exon 11. This mutation has been reported
previously in women with breast cancer [28]. Splicing
mutations outside the canonical AG-splice acceptor site
and GT splice donor sites are relatively common in A-T
patients [16] and ATM exon skipping has been reported
previously for A-T families including skipping of exons
4, 6, 7, 8, 9, 10, 11, 12, 14 or 16 http://chromium.liacs.
nl/lovd/refseq/ATM_codingDNA.html[29]. To deter-
mine the allelic status of these two mutations in patient
13 we employed a RT-PCR strategy that spanned both
mutation sites within a single amplicon ie. by using pri-
mers complimentary to sequence from exon 10 and
exon 15, respectively. Nucleotide sequence of the differ-
ent sized amplicons indicated that the two ATM
Figure 1 Western analysis of protein extracts from LCLs established from patients listed in Table. 1. A & B. Basal levels of the ATM
protein. C. ATM protein levels before and 1 hour after an IR exposure of 5 Gy. Western blots were probed with the ATM-2C1 antibody (Abcam).
Obligate A-T heterozygote (ATH); Highest ATM expresser (HE); Non-reactor controls (C1-3).
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mutations for patient 13 were not allelic but located on
different chromosomes. The RT-PCR sequence chroma-
togram for the c.1918A>T mutation (Fig. 3A) further
indicated a reduced level of that allele that skips exon
11, presumably the result of nonsense mediated decay.
For low expressers 11 and 16 there was no evidence
for a mutation in the ATM coding sequence. Patient 11
had a higher than normal ICA count (see below) and an
unusual ATM kinase activity profile, therefore, we per-
formed a full genomic sequence analysis of the ATM
gene for this patient spanning the intron-exon bound-
aries for all 66 exons. We found no evidence for a dele-
terious mutation in the ATM gene for patient 11.
3.4 ATM Kinase Activity
To determine the functional significance of low levels of
the ATM protein we tested all low expressing patient
cell lines for ATM kinase activity [20] and IR-induced
chromosomal aberrations (ICA). In vitro ATM kinase
activity was measured using ATM immunoprecipitation
as described previously [18] followed by immunoblotting
with the anti-pS1981 antibody to determine autopho-
sphorylation, and also by using p53 as a substrate for
ATM (Figs. 4, 5 &6). We found that 3/4 of the low
expressers (patients 11, 13 & 16) had reduced ATM
kinase activity (Figs. 4, 5, 6 &7 and reviewed in Table
1). Patient 16 showed no detectable level of ATM kinase
activity (Fig. 6). The very low level of ATM protein for
patient 13 (Fig. 4, 5, 6) was associated with an equally
low level of ATM autophosphorylation. This was con-
firmed using the GST-p53 substrate which showed a
small level of radiation-induced phosphorylation that
was only evident at the higher dose of 10 Gy (Fig. 4,
lower panels), see longer exposure. After immunopreci-
pitation, low expresser patient 11 also showed a small
degree of ATM autophosphorylation, however, this
induction of ATM kinase activity was not evident when
p53 was used as the substrate (Fig. 5). Low expresser
patient 10 (35% of the ATM protein) showed no reduc-
tion in kinase activity which suggested a possible false
positive status, however, ATM kinase assays are not
strictly quantitative. The only A-T obligate heterozygote
in this study to carry a missense mutation, ATH5ABR,
had the lowest level of the ATM protein (17%) when
compared to the other ATH (Fig. 2 and see also Fig. 1A
lane 10 and Fig. 7) and low ATM kinase activity (Fig. 7).
A larger study could help here to determine the stoi-
chiometric relationship between ATM protein level and
detectable reductions in kinase activity. The A-T
affected child of ATH5ABR (ATH18ABR) had no ATM
protein and no ATM kinase activity (Fig. 7).
3.5 IR-induced chromosomal aberrations (ICA)
The number of DNA double strand breaks that persist
following exposure to IR in vitro (chromosomal aberra-
tions) is a relative measure of any inefficiency in dsDNA
damage repair. ICA counts > 1.25 per metaphase are
indicative of a deficit in DNA repair [21]. In this study
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Figure 2 Scatterplot showing the level of the ATM protein for LCLs established for the following population groups. Breast cancer
patients with no adverse reaction to radiotherapy referred to as non-reactor controls (NRC); Women with SLE; Cancer patients with severe acute
normal tissue reactions to radiotherapy (RS-acute); Patients with severe acute and late reactions (RS-A/L); Patients with only severe late reactions
(RS-Late); Obligate A-T heterozygotes (ATH - Note: the 4 highest expressing ATH carry null mutations); A-T patients (A-T). ATM protein densities
were plotted as a percentage of the level of the ‘highest ATM expresser’.
Fang et al. Genome Integrity 2010, 1:9
http://www.genomeintegrity.com/content/1/1/9
Page 6 of 12
(A) 
(B)
(C)
(D)
c.1918 A>T
Null mutation
Normal
Wild type
IVS10-6TG 
Intron 10 Exon 11
IVS10-6TG
3kb
2kb
1.5kb
1kb
1       2 3     4       5       6      7      8
Figure 3 The 2 ATM truncation mutations identified for low expresser patient 13 are non-allelic. (A) RT-PCR nucleotide sequence
chromatogram showing a novel premature termination mutation c.1918A>T: Lys640Stop (arrowed top panel) compared to the normal sequence
(lower panel). Note: the upper chromatogram shows no evidence of expression of the normal ‘A’ nucleotide from the alternate allele. (B) RT-PCR
amplification of the ATM cDNA for patient 13 using 8 sets of overlapping primers (supplementary table 1) returned single amplicons (lanes 2-8)
with the exception of Fragment 1 (lane 1) which returned a dual amplicon suggestive of a deletion in one allele. (C) RT-PCR nucleotide
sequence chromatograms for these two amplicons; sequence from the normal allele (upper panel) and the shorter allele (lower panel). Note: the
shorter allele is missing sequence from exon 11. (D) Genomic sequencing revealed a heterozygous variation IVS10-6T–>G (1065del164) within
the extended 5’ splice site of intron 10 (ATM Ref Seq. NM_000051). Extended RT-PCR sequencing across both mutations confirmed these two
mutations were non-allelic (result not shown).
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the mean for normal controls was < 1. The two A-T cell
lines used here as ATM null controls had mean levels of
ICA > 3. The 4 low expresser patients (patients 10, 11,
13 and 16) had ICA counts of 1.44, 1.34, 1.52, and 0.94,
respectively (Table 1). The ICA count for ATH5ABR
was 2.3. ICA counts in this study correlated more con-
sistently with clinical radiosensitivity than with in vitro
cellular proliferation assays following IR (Table 2) or
clonogenic assays (results not shown) [25]. For example,
low expresser patient 13, the patient with the compound
pathogenic ATM genotype and the lowest level of ATM
protein (~10%) and very low ATM kinase activity and a
high ICA count had an average SF2 value of 41.6 which
was higher than the other 3 low ATM expresser patients
10, 11 and 16 (22.4, 25.7 and 33.8, respectively) and
comparable to that for non-reactor controls (39.5 ±
5.98) and higher compared with the SF2 value for
women with SLE (33.0 ± 3.19) (Table 2).
Discussion
Informative radiotherapy biomarkers have great poten-
tial to improve risk assessments and radiotherapy out-
comes. The pathological risk for clinical radiosensitivity
and/or breast cancer associated with ATM mutations is
considered to be low but in most risk assessments this
risk could better be described as uncertain due to the
omission of functional data [9][11][12]. Few of the ATM
variants/mutations reported to date have been function-
ally characterised and the common omission of func-
tional data from ATM related risk assessments [9,11,12]
IP: ATM kinase
WB: ATM
GST-p53-32P
GST-p53 substrate
ATH5     ATH18    sibs of ATH18
IR 5Gy - +     - +      - +     - +
Figure 4 ATM kinase activity for LCLs 1 hour after an in vitro IR exposure of 5 Gy for breast cancer patients and controls.
IP: ATM kinase
WB: ATM
GST-p53-32P
GST-p53 substrate
WB: pS1981 ATM
Patient 11   Patient 13      AT1ABR
IR 5Gy     -      +         -       +         -        +
Figure 5 ATM kinase activity for LCLs 1 hour after an in vitro IR exposure of 5 Gy for breast cancer patients and controls.
Fang et al. Genome Integrity 2010, 1:9
http://www.genomeintegrity.com/content/1/1/9
Page 8 of 12
is disconcerting especially if the data is not supportive
or conclusive. Albeit, there is uncertainty regarding the
pathological threshold level of the ATM protein and the
extent to which ATM protein levels vary independent of
ATM mutation status.
Severe reactions to radiotherapy are very rare entities
and our cohort of 20 radio-hypersensitive individuals
represented patients recruited from 3 of Australia’s lar-
ger cancer centres. A total of 12 members of this cohort
had been treated for breast cancer and 4 of this 12 had
levels of the ATM protein < 55% compared with the
mean for non-reactor controls. Subsequently all 4 of
these ‘low ATM expressers’ were found to have either
reduced ATM kinase activity (3/4) and/or increased ICA
counts (3/4) and/or ATM mutations (2/4) (summarised
in Table 1). Note: The study of the cellular stress
response to IR reported here may bring forward a cellu-
lar phenotype for some individuals including some A-T
heterozygotes where an early age at presentation would
otherwise be unexpected. A-T patients (ie, homozygotes
with the clinical syndrome) present at a young age,
whereas obligate A-T heterozygotes usually remain
undetected and are generally asymptomatic except for
risk of breast cancer and radiosensitivity. A larger study
including A-T families could help refine ATM protein
thresholds for risk of both clinical radiosensitivity and
breast cancer.
The persistence of ICA in 3/4 of the low expressers
provided a particularly clear link with the clinical radio-
sensitivity for these patients, two of whom manifest
both severe acute and severe late reactions. Of these 2
patients, patient 11, had a high ICA count and low
IP: ATM kinase
WB: ATM
GST-p53-32P
GST-p53 substrate
Patients        16              15             11              13
IR 5Gy - + - + - + - +
Figure 6 ATM kinase activity for LCLs 1 hour after an in vitro IR exposure of 5 Gy for breast cancer patients and controls.
IP: ATM kinase
WB: ATM
GST-p53-32P
GST-p53 substrate
ATH5     ATH18    sibs of ATH18
IR 5Gy - +     - +      - +     - +
Figure 7 ATM kinase activity for LCLs 1 hour after an in vitro IR exposure of 5 Gy for breast cancer patients and controls. Obligate
heterozygote ATH5ABR ~ the father of an A-T patient and his two siblings had high ICA counts of 2.18, 3.24, 2.50 & 2.48, respectively. The
AT1ABR cell line, used here as a positive control, was originally derived from an A-T patient homozygous for a small (3 amino acid) in-frame
deletion that destabilises the protein and which was reported previously with very low levels of mutant ATM protein [18].
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ATM kinase activity but no ATM mutation at either the
cDNA or genomic level suggesting that ATM protein
levels may represent an independent risk factor for clini-
cal radiosensitivity [30-33]. Compared to ICA, cellular
proliferation assays in this study were not as reliable an
indicator of clinical radiosensitivity due to variation in
cell cycling parameters and where some LCLs demon-
strate markedly reduced and often variable growth rates
after replating and/or variable growth rates at different
cell densities. The increased complexity and extended
duration of proliferation assays can further compound
these variations.
Greater knowledge regarding the functional deficiency
associated with any ATM mutation will help clarify the
associated pathological risk. The present study demon-
strates that levels of haploinsufficiency associated with a
range of ATM null mutations do vary between indivi-
duals (Fig. 2). Results further suggest that haploinsuffi-
ciency is a risk factor only when the associated level of
protein falls below a threshold for breast cancer or clini-
cal radiosensitivity. From the results of this small pilot
study we propose a tentative ATM threshold of ~55% for
risk of clinical radiosensitivity for breast cancer patients
compared to the mean for non-reactor controls. Haploin-
sufficiency can also result from missense mutations. The
obligate A-T heterozygote ATH5ABR who carried what
could have been regarded as a ‘low-risk’ missense variant
(Leu950Arg) [12] due to its location outside the evolu-
tionary conserved domains of ATM to which missense
variants have been most closely tied to A-T (namely the
FAT, kinase and FATC domains located at amino acid
positions 2096-2489, 2711-2962 and 3024-3056, respec-
tively within ATM [12,27,34]) was associated with a very
low level of the ATM protein (~17%), reduced ATM
kinase activity and a high ICA count [13] to provide the
strongest indication of pathogenic potential. Results also
suggest that individuals carrying the same mutation may
express different levels of the ATM protein. For example,
radiosensitive breast cancer patient 13 had a non-allelic
compound pathogenic ATM genotype comprised of a
truncating Lys640Stop mutation on one allele and on the
other allele a splice site mutation c.1066-6T > G (that
caused skipping of exon 11 and premature termination in
exon 12 sequence) that reduced transcript stability and
the protein level (~10%) but did not result in any of the
more severe early-onset A-T pathologies. In contrast,
homozygosity for this same splice site mutation was
reported previously in an A-T patient with < 10% of the
full length ATM protein [29] indicating the ‘leaky’ nature
of this mutation and suggesting variable expressivity
between individuals. The coexistence of pathological
thresholds and variable expressivity of ATM protein
levels presents opportunities and pitfalls for future risk
assessments that could best be managed with the deter-
mination of ATM protein levels for all subjects regardless
of mutation status.
Do ATM protein levels represent a practical biomar-
ker for assessing risk of radiotherapy toxicity or breast
cancer? Unlike the ATM kinase assay, ATM protein
quantitation is quantitative yet at this point in time both
assays require large cell numbers. With modern
advances in mass spectrometry [22,24] it may soon be
possible to evaluate ATM levels in single cell analyses -
a development that would greatly expedite testing in the
clinic. There may also be future scope to determine
tumour thresholds for ATM for optimum IR control of
cancer. The 4 ‘low ATM expressers’ described here with
breast cancer did not recur within the 2-5 year period
following radiotherapy. In addition, low ATM protein
levels are usually associated with more advanced stages
of breast cancer [15,35] with a notable exception being
the high level expression of ATM in a radioresistant
malignant myoepithelioma of the breast [36] which
together suggest that there may exist an ATM threshold
for optimum radiotherapy control.
Conclusion
ATM mutations are generally considered low risk alleles
for breast cancer and clinical radiosensitivity. Results
described here suggest that ATM protein levels may
represent an independent biomarker for individuals at
high-risk of clinical radiosensitivity. We propose a tenta-
tive ATM threshold of ~55% for risk of adverse normal
tissue reactions to radiotherapy and ~10% for the more
severe A-T related pathologies.
Table 2 LCL survival fractions following exposure to 2 Gy
IR
Patients SLE Non-Reactor
Controls
Low ATM
Expressers
A-T
Average SF2
(%)
30.40 37.50 23.1 (10) 17.2
36.55 38.62 25.7 (11) 9.3
32.08 48.83 41.6 (13
30.88 36.65 33.8 (16
32.98 45.51
36.80 31.21
33.42 39.11
29.46 35.45
34.45 33.96
34.83
35.18
30.25
27.18
38.35
Mean SF2 33.0 ±
3.19
39.5 ± 5.98
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